Upfront Genotyping of DPYD* 2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Authors :: Deenen, MJ
Meulendijks, Didier
Cats, A
Sechterberger, MK
Severens, Hans
Boot, Henk
Smits, PH
Rossing, Hilde
Mandigers, CMPW
Soesan, Marcel
Beijen, JH
Schellens, JHM
Deenen, MJ
Meulendijks, Didier
Cats, A
Sechterberger, MK
Severens, Hans
Boot, Henk
Smits, PH
Rossing, Hilde
Mandigers, CMPW
Soesan, Marcel
Beijen, JH
Schellens, JHM
Source :: Deenen , MJ , Meulendijks , D , Cats , A , Sechterberger , MK , Severens , H , Boot , H , Smits , PH , Rossing , H , Mandigers , CMPW , Soesan , M , Beijen , JH & Schellens , JHM 2015 , ' Upfront Genotyping of DPYD* 2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis ' , Journal of Clinical Oncology , vol. 34 , no. 3 .
Publication Year :: 2015

Database :: OAIster
Journal :: Deenen , MJ , Meulendijks , D , Cats , A , Sechterberger , MK , Severens , H , Boot , H , Smits , PH , Rossing , H , Mandigers , CMPW , Soesan , M , Beijen , JH & Schellens , JHM 2015 , ' Upfront Genotyping of DPYD* 2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis ' , Journal of Clinical Oncology , vol. 34 , no. 3 .
Notes :: application/pdf, English
Publication Type :: Electronic Resource
Accession number :: edsoai.on1313619224
Document Type :: Electronic Resource

Tools